Lamivudine/Zidovudine Viatris (Zidovudine, Lamivudine)

Both lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors. After oral absorption, they are converted inside cells to active triphosphate forms that compete with natural nucleosides, become incorporated into viral DNA, and cause chain termination, thereby blocking HIV replication.

The exact dose and dosing schedule of Lamivudine/Zidovudine are determined by the prescribing healthcare professional based on the patient’s age, weight, renal function, treatment history, and any concomitant medications. Patients should follow the prescriber’s instructions precisely.

Safety data for lamivudine/zidovudine in pregnancy and lactation are limited. The drug may be used if the potential benefit to the mother outweighs potential risks to the fetus or infant. Clinicians should discuss individual risks and benefits with the patient.

To request Lamivudine/Zidovudine, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine/Zidovudine is a fixed‑dose NRTI combination offering convenience compared with taking the agents separately. Compared with newer integrase inhibitors, it may have a different side‑effect profile and resistance pattern, making it suitable for certain treatment‑experienced patients or where cost considerations are important.

Store Lamivudine/Zidovudine tablets at room temperature, below 25 °C, in the original container. Protect the product from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

Lamivudine/Zidovudine is taken orally, usually as a tablet, with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance to ensure consistent absorption.

Serious adverse events include lactic acidosis, severe hepatic steatosis, bone‑marrow suppression leading to pancytopenia, and hypersensitivity reactions that may involve rash, fever or organ dysfunction. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to lamivudine, zidovudine, or any tablet excipients should avoid the product. It is also contraindicated in individuals with severe bone‑marrow disease or uncontrolled liver disease, and should be used with caution in pregnant or breastfeeding women.